Search

Israel is already a fertility treatment superpower. Now it is turning to AI to do even better

Updated: Jul 5

AiVF, which developed a fully operational AI-based IVF software platform, raised $25 million in Series A.


AiVF team. Photo source: company website
AiVF team. Photo source: company website

AiVF, an Israeli company which developed a fully operational AI-based IVF (in-vitro fertilization) software platform, announced last week it has raised $25 million in a Series A round led by Insight Partners, a New York-based venture capital and private equity firm.


The company will use the funding to fuel adoption of the company’s AI platform, EMA™ in the United States and Europe, expand its work force, and develop additional solutions to drive a new generation of digital fertility care.


According to the company, its platform provides an optimized end-to-end IVF journey to individuals seeking Assisted Reproductive Technologies for their family building. Its advanced machine learning and computer vision algorithms developed by AiVF have the potential to shorten the time to pregnancy, says the company, and increase IVF predictability and success rates.


“Our vision is to help individuals realize their dream to become families,” says Daniella Gilboa, AiVF co-founder, CEO, and clinical embryologist. “We are delivering innovative products to the market while enhancing the science of reproductive medicine to drive the next generation of fertility care.”


In the 44 years since the birth of the world’s first IVF baby, Louise Brown, over 8 billion IVF babies have been born worldwide. And while its technology has advanced by leaps and bounds, it has still remained costly.


It is perhaps not surprising that AiVF start-up was born in Israel – a country which not only leads the OECD fertility chart at 3.4 children per women – but is also a global fertility treatment powerhouse.


Any Israeli woman, married or single, is eligible for an unlimited number of IVF rounds until she has two children, or until the age of 45. If a woman chooses to continue treatment using a donor egg before having two children – her treatments are subsidized until the age of 54.

46 views0 comments